Harrow (HROW) Q4 Earnings and Revenues Top Estimates
Harrow (HROW) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.27 per share a year ago.
Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025
Harrow Health's robust distribution platform and patented eye care products create a strong moat, offering an attractive entry point after the recent stock price correction. Catalysts in 2025 could come from a successful Triesence launch and potential NDA filing for Melt pharma, where HROW has a material stake. The main risk is the company's loss in Q3 2024 despite recent acquisitions, so more revenue growth alongside controlled costs is needed for the stock to work from here.
Those Derisked Baby Bonds Of Harrow, Inc.
Harrow's 11.875% Senior Notes due 2027 are attractive baby bonds with a healthy leverage percentage of 13.8%, indicating strong creditworthiness and low debt. Harrow funds operations through product sales, not debt or frequent equity raises, showcasing a robust financial position and sustainable business model. VEVYE, IHEEZO, and Triesence show significant growth potential, with Triesence addressing supply chain issues and justified price hikes, ensuring strong future demand.
Harrow: The Triesence Relaunch
Harrow's relaunch of Triesence, a preservative-free corticosteroid, addresses a critical unmet need in ophthalmology, offering safer and more effective treatment options for eye care professionals. Triesence's unique formulation and absence of preservatives make it superior to alternatives like Kenalog, despite its higher price point and previous supply chain issues. Harrow's acquisition and relaunch of Triesence, with 39,000 units available, positions the company for significant market growth, targeting over 500,000 units annually.
Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript
Harrow, Inc. (NASDAQ:HROW ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Jamie Webb - Director, Communications & Investor Relations Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann & Company Mayank Mamtani - B. Riley Securities Operator Good morning, and welcome to Harrow's Third Quarter 2024 Earnings Conference Call.
Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates
Harrow (HROW) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.
Harrow: VEVYE And Its Impact On The DED Market
Harrow Inc. experienced a brief 20% stock drop in October but quickly recovered, showing resilience despite recent revenue channel underperformance. HROW's new branded pharmaceutical products, especially VEVYE, are driving a diversified revenue stream, with VEVYE showing exceptional growth and market penetration since its late 2023 launch. VEVYE's strong refill rates and expanding prescriber base indicate significant patient benefits and long-term revenue potential, supported by a patent extending to 2039.
Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Will Harrow (HROW) Report Negative Earnings Next Week? What You Should Know
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best Momentum Stocks to Buy for November 6th
HROW, ORLA and SWDBY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 6, 2024.
Harrow (HROW) Upgraded to Strong Buy: What Does It Mean for the Stock?
Harrow (HROW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Harrow (HROW) Could Rally 25.95%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Harrow (HROW). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
